| Literature DB >> 28453477 |
Ali Yilmaz1, Tim Geddes1, BeomSoo Han2, Ray O Bahado-Singh1, George D Wilson1, Khaled Imam1, Michael Maddens1, Stewart F Graham3.
Abstract
Using 1H NMR metabolomics, we biochemically profiled saliva samples collected from healthy-controls (n = 12), mild cognitive impairment (MCI) sufferers (n = 8), and Alzheimer's disease (AD) patients (n = 9). We accurately identified significant concentration changes in 22 metabolites in the saliva of MCI and AD patients compared to controls. This pilot study demonstrates the potential for using metabolomics and saliva for the early diagnosis of AD. Given the ease and convenience of collecting saliva, the development of accurate and sensitive salivary biomarkers would be ideal for screening those at greatest risk of developing AD.Entities:
Keywords: 1H NMR; Alzheimer’s disease; metabolomics; mild cognitive impairment
Mesh:
Year: 2017 PMID: 28453477 DOI: 10.3233/JAD-161226
Source DB: PubMed Journal: J Alzheimers Dis ISSN: 1387-2877 Impact factor: 4.472